Stallergenes opens new pharmaceutical production unit in Paris

Designed to comply with the EMEA (European Medicines Agency) and FDA standards, this unit is expected to produce desensitization treatments for all markets, primarily in Europe and North America.

This investment, worth more than E20 million, will incorporate the production of the active substance for the Oralair Grasses tablet and increase the production capacity for Staloral, to meet the needs of an expanding international marketplace, the company said.

Oralair Grasses is said to be a fast-dissolving sublingual desensitization tablet indicated in allergic rhino-conjunctivitis caused by grass pollen for patients with moderate to severe symptoms unsatisfied with or inadequately controlled by symptomatic treatments.

Staloral is an NPP (named patient product) sublingual solution (drops to be placed under the tongue) of allergen extracts. Staloral is indicated in allergic rhino-conjunctivitis caused by pollen, dust mites, mould and dander (animal hair).

Albert Saporta, chairman and CEO of Stallergenes, said: “For Stallergenes, this investment marks a major step forward. This new production unit will help the company break into the tough US market and increase its production capacity tenfold.”